Northern Trust
NRIX icon

Northern Trust’s Nurix Therapeutics NRIX Stock Holding History

Northern Trust’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3M Buy
876,070
+21,604
+3% +$368K ﹤0.01% 1771
2026
Q1 		$13.2M Buy
854,466
+48,784
+6% +$809K ﹤0.01% 1919
2025
Q4 		$15.3M Buy
805,682
+125,673
+18% +$1.81M ﹤0.01% 1843
2025
Q3 		$6.28M Buy
680,009
+26,476
+4% +$275K ﹤0.01% 2372
2025
Q2 		$7.44M Sell
653,533
-46,784
-7% -$506K ﹤0.01% 2231
2025
Q1 		$8.32M Buy
700,317
+40,529
+6% +$678K ﹤0.01% 2149
2024
Q4 		$12.4M Buy
659,788
+92,933
+16% +$2.13M ﹤0.01% 1999
2024
Q3 		$12.7M Buy
566,855
+128,766
+29% +$2.92M ﹤0.01% 1925
2024
Q2 		$9.14M Buy
438,089
+34,079
+8% +$531K ﹤0.01% 2050
2024
Q1 		$5.94M Sell
404,010
-12,804
-3% -$138K ﹤0.01% 2354
2023
Q4 		$4.3M Sell
416,814
-24,038
-5% -$165K ﹤0.01% 2587
2023
Q3 		$3.47M Buy
440,852
+12,210
+3% +$111K ﹤0.01% 2651
2023
Q2 		$4.28M Buy
428,642
+28,624
+7% +$292K ﹤0.01% 2587
2023
Q1 		$3.55M Sell
400,018
-7,925
-2% -$82.6K ﹤0.01% 2659
2022
Q4 		$4.48M Buy
407,943
+4,201
+1% +$50.7K ﹤0.01% 2549
2022
Q3 		$5.26M Buy
403,742
+15,548
+4% +$246K ﹤0.01% 2456
2022
Q2 		$4.92M Buy
388,194
+83,657
+27% +$948K ﹤0.01% 2522
2022
Q1 		$4.27M Sell
304,537
-11,484
-4% -$204K ﹤0.01% 2672
2021
Q4 		$9.15M Sell
316,021
-4,985
-2% -$151K ﹤0.01% 2296
2021
Q3 		$9.62M Buy
321,006
+24,116
+8% +$744K ﹤0.01% 2302
2021
Q2 		$7.88M Buy
296,890
+64,213
+28% +$1.89M ﹤0.01% 2538
2021
Q1 		$7.23M Buy
232,677
+94,865
+69% +$3.59M ﹤0.01% 2510
2020
Q4 		$4.53M Buy
137,812
+4,474
+3% +$148K ﹤0.01% 2733
2020
Q3 		$4.65M Buy
+133,338
New +$3.36M ﹤0.01% 2573

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust's NRIX Position: Q2 2026 in Review

Northern Trust increased its Nurix Therapeutics (NRIX) stake by 2.5% in Q2 2026, buying an estimated $368K and bringing the position to 876,070 shares worth $21.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

Northern Trust first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Northern Trust held 876,070 shares of Nurix Therapeutics worth $21.3M as of Q2 2026.
  • Northern Trust bought 21,604 Nurix Therapeutics shares in Q2 2026, an estimated $368K.
  • Nurix Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1771 holding.
  • Northern Trust first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.